Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
| dc.rights.license | open | en_US |
| dc.contributor.author | DEMUTH, Stanislas | |
| dc.contributor.author | COLLONGUES, Nicolas | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | AUDOIN, Bertrand | |
| dc.contributor.author | AYRIGNAC, Xavier | |
| dc.contributor.author | BOURRE, Bertrand | |
| dc.contributor.author | CIRON, Jonathan | |
| dc.contributor.author | COHEN, Michaël | |
| dc.contributor.author | DESCHAMPS, Romain | |
| dc.contributor.author | DURAND-DUBIEF, Françoise | |
| dc.contributor.author | MAILLART, Elisabeth | |
| dc.contributor.author | PAPEIX, Caroline | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | RUET, Aurelie | |
| dc.contributor.author | ZEPHIR, Helene | |
| dc.contributor.author | MARIGNIER, Romain | |
| dc.contributor.author | DE SEZE, Jerome | |
| dc.date.accessioned | 2024-03-04T15:34:26Z | |
| dc.date.available | 2024-03-04T15:34:26Z | |
| dc.date.issued | 2023-07-25 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188569 | |
| dc.description.abstractEn | Background and ObjectivesExit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk.MethodsWe describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS). All patients met the 2015 International Panel for NMO Diagnosis (IPND) diagnostic criteria for NMOSD. A computerized screening of the registry extracted patients with rituximab de-escalations and at least 12 months of subsequent follow-up. We searched for 7 de-escalation regimens: scheduled discontinuations or switches to an oral treatment after single infusion cycles, scheduled discontinuations or switches to an oral treatment after periodic infusions, de-escalations before pregnancies, de-escalations after tolerance issues, and increased infusion intervals. Rituximab discontinuations motivated by inefficacy or for unknown purposes were excluded. The primary outcome was the absolute risk of NMOSD reactivation (one or more relapses) at 12 months. AQP4+ and AQP4- serotypes were analyzed separately.ResultsWe identified 137 rituximab de-escalations between 2006 and 2019 that corresponded to a predefined group: 13 discontinuations after a single infusion cycle, 6 switches to an oral treatment after a single infusion cycle, 9 discontinuations after periodic infusions, 5 switches to an oral treatment after periodic infusions, 4 de-escalations before pregnancies, 9 de-escalations after tolerance issues, and 91 increased infusion intervals. No group remained relapse-free over the whole de-escalation follow-up (mean: 3.2 years; range: 0.79-9.5), except pregnancies in AQP+ patients. In all groups combined and within 12 months, reactivations occurred after 11/119 de-escalations in patients with AQP4+ NMOSD (9.2%, 95% CI [4.7-15.9]), from 0.69 to 10.0 months, and in 5/18 de-escalations in patients with AQP4- NMOSD (27.8%, 95% CI [9.7-53.5]), from 1.1 to 9.9 months. © American Academy of Neurology. | |
| dc.description.sponsorship | Observatoire Français de la Sclérose en Plaques - ANR-10-COHO-0002 | en_US |
| dc.language.iso | EN | en_US |
| dc.title.en | Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder | |
| dc.title.alternative | Neurology | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1212/WNL.0000000000207443 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 37290967 | en_US |
| bordeaux.journal | Neurology | en_US |
| bordeaux.page | E438-E450 | en_US |
| bordeaux.volume | 101 | en_US |
| bordeaux.hal.laboratories | Neurocentre Magendie - U1215 | en_US |
| bordeaux.issue | 4 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | Bordeaux INP | |
| bordeaux.institution | CNRS | |
| bordeaux.institution | INRAE | |
| bordeaux.institution | Arts et Métiers | |
| bordeaux.team | Relations glie-neurone | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04488723 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-03-04T15:34:29Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2023-07-25&rft.volume=101&rft.issue=4&rft.spage=E438-E450&rft.epage=E438-E450&rft.au=DEMUTH,%20Stanislas&COLLONGUES,%20Nicolas&AUDOIN,%20Bertrand&AYRIGNAC,%20Xavier&BOURRE,%20Bertrand&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||